GT Biopharma Corp (GTBP) Total Debt to Capital

GT Biopharma - graphic logo of issuer GTBP

The market trend for the total debt-to-equity ratio of GT Biopharma, Inc. (GTBP) stands at 0.00. The firm's financial position relies on clinical test results and external contracts, as there is currently no operating income. Growth potential is based on the TriKE platform, which effectively directs immune cells against leukemias, while the environmental footprint remains minimal due to a virtual drug development format.

gtbiopharma.com (GTBP): Debt to Equity Ratio from 07/04/2022 to 10/31/2026

Metric breakdowns and analytics for GT Biopharma Corporation (GTBP)

- share price and consensus valuation forecast:
Stock Price GT Biopharma|GTBP - Consensus Target
- market capitalization details:
Market Capitalization GT Biopharma|GTBP - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share GT Biopharma|GTBP - Accounting Capitalization|Market Capitalization to Book Value Ratio gtbiopharma.com|GTBP - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital GT Biopharma, Inc.|GTBP - Long-Term Liabilities to Capital|Short-Term Debt to Equity GT Biopharma, Inc.|GTBP - Aggregate Debt Obligations|Debt to Book Value GT Biopharma|GTBP - Company Long-Term Loans and Borrowings|Company Short-Term Debts GT Biopharma|Quick Liquidity gtbiopharma.com
- net income and valuation ratios data:
GTBP - Company Net Income
Fundamental company valuation:GT Biopharma
Finished products of GT Biopharma, Inc.

For the small biotech company GT Biopharma, Inc. (GTBP), which faces a high burn rate and regulatory risks, controlling the financing structure is critical. By analyzing the total debt-to-equity ratio, an investor assesses the proportion of borrowed funds relative to equity, where a downward trend confirms a reduction in debt load, while an increase indicates dangerous financial leverage that limits business resilience.

Competitor analysis for GT Biopharma, Inc.

TGTX (TG Therapeutics) - Total Debt to Capital|Total Debt to Equity Ratio Arcellx Inc (ACLX)|Total Debt to Capital IRON|Total Debt to Capital Syndax Corp (SNDX)|Debt to Equity Kura Oncology, Inc. KURA|ADCT: Debt to Equity Ratio|Foghorn - Total Debt to Capital|Vor Biopharma, Inc. (VOR) - Total Debt to Equity Ratio|NKTX: Total Debt to Capital|Debt to Capital Coeptis Therapeutics, Inc. (COEP)|Debt to Equity Actinium Pharmaceuticals|ESLA: All Debt to Shareholders' Equity Ratio|Total Debt to Equity Ratio CASI (CASI Pharmaceuticals)|MRKR (markertherapeutics.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital INAB (IN8bio, Inc)|Eterna Therapeutics, Inc. - Debt to Equity|APTO - Debt to Equity|BPTH: Debt to Equity|MEI Pharma (MEIP) - Debt to Equity|Debt to Capital Vincerx Pharma (VINC)